Suzuki Yutaro, Murakami Hideki, Kawaguchi Koji, Tanigushi Tetsuo, Fujii Makiko, Shinjo Keiko, Kondo Yutaka, Osada Hirotaka, Shimokata Kaoru, Horio Yoshitsugu, Hasegawa Yoshinori, Hida Toyoaki, Sekido Yoshitaka
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan.
Mol Med Rep. 2009 Mar-Apr;2(2):181-8. doi: 10.3892/mmr_00000081.
Malignant mesothelioma (MM) is a highly aggressive neoplasm, which is associated with asbestos exposure. The dysregulated phosphatidylinositol 3-kinase (PI3K)-AKT pathway plays an important role in cell proliferation, survival and motility in various cancers. In this study, we analyzed the activation status and underlying mechanisms of this pathway in MM cells using 21 cell lines. AKT activation was observed in 13 (62%) of the 21 MM cell lines under serum-starved conditions. Two cell lines, ACC-MESO-1 and Y-MESO-25, showed no expression of PTEN protein, while 7 other cell lines showed low expression of PTEN mRNA and protein compared to expression levels in an immortalized normal mesothelial cell line, MeT-5A. We found that PTEN inactivation in the ACC-MESO-1 and Y-MESO-25 lines was due to a 39.4-kb deletion including PTEN exon 2, and to a 7.7-kb deletion including exon 1, respectively. Re-expression of PTEN in these cells reduced the activity of colony formation in vitro. In contrast, no mutation of PIK3CA or LKB1 was found in any of the MM cell lines. These findings suggest that AKT is frequently activated in MM cells, in part due to the downregulation of PTEN. Thus, the PI3K-AKT signaling pathway is a potential therapeutic target for MM.
恶性间皮瘤(MM)是一种侵袭性很强的肿瘤,与石棉暴露有关。磷脂酰肌醇3激酶(PI3K)-AKT信号通路失调在多种癌症的细胞增殖、存活和迁移中起重要作用。在本研究中,我们使用21种细胞系分析了该通路在MM细胞中的激活状态及潜在机制。在血清饥饿条件下,21种MM细胞系中有13种(62%)观察到AKT激活。两种细胞系ACC-MESO-1和Y-MESO-25未显示PTEN蛋白表达,而与永生化正常间皮细胞系MeT-5A相比,其他7种细胞系显示PTEN mRNA和蛋白低表达。我们发现,ACC-MESO-1和Y-MESO-25细胞系中PTEN失活分别是由于包含PTEN外显子2的39.4 kb缺失和包含外显子1的7.7 kb缺失。在这些细胞中重新表达PTEN可降低体外集落形成活性。相反,在任何MM细胞系中均未发现PIK3CA或LKB1突变。这些发现表明,AKT在MM细胞中频繁激活,部分原因是PTEN下调。因此,PI3K-AKT信号通路是MM的一个潜在治疗靶点。